In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.
|Poll|May 3, 2018
Mini Quiz: Treatment-Resistant Bipolar Disorder
Author(s)Charles B. Schaffer, MD
What are the guidelines for working with patients who do not respond to FDA-approved medications for bipolar disorder?
Advertisement
Which of the following interventions can be useful in treating treatment-resistant bipolar disorder?
Advertisement
Related to this article
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5